As the calendar approaches the middle of the year, it is a good time to review the Fourth Circuit's recent class-action decisions—and there have been a number of them.
On April 8, 2022, the U.S. Court of Appeals for the Ninth Circuit, sitting en banc, re-certified three classes of packaged tuna buyers, rejecting a Ninth Circuit panel-majority’s per se.
Among the drug pricing developments to watch in 2022, those at the top include legislation that would allow Medicare price negotiation and alter antitrust rules for the pharmaceutical.
2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology.
On August 13, 2021, in a decision that largely flew under antitrust and patent practitioners' radars, U.S. District Judge Lucy H. Koh mostly denied a motion to dismiss in the alleged "reverse payment" case.